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Abstract: 
Objective 
The current research was conducted to evaluate episodes of Congestive Heart Failure (CHF) among dialysis 
patients; it`s frequency and prognosis in patients attending public healthcare institutes of Quetta city, Pakistan.  
Methods 
This is a multicenter cohort study conducted at two public healthcare institutes of Quetta city, Pakistan. Data of 117 
patients for one year was screened from the official records and evaluated retrospectively to identify variables of 
interest. Data was collected through a validated information sheet. SPSS v.20 was used for data analysis and data 
was described descriptively.   
Results 
All patients had End-Stage Renal Disease (ESRD) and were on regular maintenance hemodialysis therapy. Out of 
all selected patients, 7.7 % patients had Non-Insulin Dependent Diabetes Mellitus, 4.3% patients had Ischemic 
Heart Disease, 78.6% had Left Ventricular Hypertrophy and 80.34% had Cardiomyopathy. Forty five patients 
(38.46%) were confirmed with CHF. Thirty seven (31.6%) of those had systolic dysfunction, 8 (6.8%) had diastolic 
dysfunction and 4 (3.4%) had both systolic and diastolic dysfunction. Additionally, 13 (28.9%) patients developed de 
novo CHF. Recurrence of CHF was observed in 26 patients (57.7%) whereas among the CHF group, eleven 
patients died during the study period presenting a mortality rate of 24% in CHF group (Table 5).  
Conclusion 
The incidence of CHF was relatively high in our study population of ESRD. Frequent recurrence of the disease, re-
hospitalization and enhanced mortality in our study population is evident of adverse prognosis of CHF in ESRD 
population.  
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INTRODUCTION: 
Heart Failure (HF) is defined as a complex clinical 
syndrome that can result from any structural or 
functional cardiac disorder that impairs the ability of 
the ventricle to fill or eject blood [1]. The diagnosis of 
HF relies on clinical examination and can be 
challenging. Heart failure has been rated as an epidemic 
condition and is a staggering clinical and public health 
problem that is associated with significant mortality, 
morbidity, and healthcare expenditures [1]. In addition 
to heart failure, congestive heart failure (CHF) is 
cardiovascular complication in which heart becomes 
unable to supply sufficient amount of blood to meet 
the metabolic requirements and fulfill oxygen 
demand of the body [2] (Malik, Tuka, Mokrejsova, 
Holaj, & Tesar, 2009). It is increasingly seen as a 
major public health problem that needs to be 
adequately addressed [3]. Within this context, there is 
increasing evidence that chronic kidney disease 
(CKD) itself is a key contributor to severe cardiac 
damage and equally CHF is a key cause of 
advancement of CKD [4,5]. In addition, multiple 
mechanisms can exacerbate CHF symptoms in 
patients with end stage renal disease (ESRD). Several 
factors and circumstances more specific to dialysis 
patients may contribute to the risk of sudden cardiac 
death ( [6]. In line with what is reported, Harnett et al 
in their study identified older age, anemia, 
hypoalbuminemia, high diastolic blood pressure, and 
systolic dysfunction as variables resulting in CHF 
[7]. Other factors which play an important role in 
worsening of CHF may result from hypertension 
(HTN), acute renal failure (ARF), chronic renal 
disease (CKD) and end stage renal disease (ESRD) in 
dialysis recipients [8]. Additionally, CHF itself 
contributes to the development of ESRD [9].  
Congestive heart failure is an independent risk factor 
for early mortality in ESRD patients [10]. In the 
ESRD population, hemodialysis (HD) also 
contributes by itself to the development of CHF [11]. 
Overall, the incidence of CHF is growing in both the 
general and ESRD populations [2,12,13]  but is 
extremely prevalent among established patients on 
renal replacement therapy (dialysis) and is a 
significant predictor of death [14] (Stack & 
Bloembergen, 2001). The development of CHF at the 
initiation of ESRD is an adverse and independent 
prognostic indicator of mortality [7], whereby 
numerous patients having CHF often fail to respond 
to CHF treatment and advance to end stage CHF with 
numerous hospitalizations, reduced quality of life, 
progressive CKD which may lead to other 
cardiovascular diseases within a short period of time 
[15].  
The situation is not different in Pakistan and CKD is 
also rapidly growing in the country due to increased 
prevalence of Diabetes Mellitus, HTN and 
nephrolithiasis [16]. However, there is scarcity of 
information on patients with CHF and ESRD from 
Pakistan. Consequently, the current research was 
conducted to evaluate CHF in dialysis patients, it`s 
prevalence, incidence and prognosis among patients 
attending public healthcare institutes in Quetta city, 
Pakistan.  Subsequently, use this information to 
suggest ways of improving the care of these patients, 
which could be monitored in future studies. 
 
METHODS: 
Study settings   
One year multicenter cohort study carried out in two 
public healthcare centers in Quetta city, Pakistan, 
namely Sandeman Provincial Hospital Quetta 
(SPHQ) and Balochistan Institute of Nephro-Urology 
Quetta (BINUQ).  
Study design and sampling 
The study was undertaken from October 2015 to 
September 2016. All patients that were registered 
during this time period were evaluated. Overall 174 
patients, 117 patients of both genders [57 males 
(48.7%) and 60 females (51.3%)] were included in 
the study. All patients had End-Stage Renal Disease 
(ESRD) and were on regular maintenance 
hemodialysis therapy. Fifty seven patients were 
enrolled from SPHQ and sixty patients from BINUQ 
based on the inclusion criteria. 
Inclusion criteria    
Patients who were clinically established for ESRD, 
recipients of regular maintenance hemodialysis for at 
least for six months, and receiving hemodialysis 
therapy at the same center, were included in the 
study. Patients not established for ESRD, recipients 
of maintenance hemodialysis less than six months, 
those who left for other centers, cities or discontinued 
therapy during the study period were excluded. 
Additionally, patients with severe mental disorder 
and who died within three months of initiation of 
study were also excluded. 
 
Data collection process 
A data collection form was designed and approved by 
the research team. This included two physicians 
practicing at BINUQ and their expertise were taken 
into consideration. The data collection form was 
piloted with 10 record files that were taken from 
SPHQ. The data collection form was then discussed 
with the nephrologist for appropriateness and validity 
related issues. Little modifications were needed and 
the amended data collection form was used for data 
collection.       
The research tool contained relevant information 
regarding the demographics and disease 
characteristics of the patients, such as age, gender, 
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hypertension; dialysis access, frequency and duration 
of HD, congestive heart failure (CHF), LV 
dysfunction (LVD), ischemic heart disease (IHD), 
left ventricular hypertrophy (LVH), diabetes of the 
patients.  
Statistical analysis 
SPSS version v 20 was used for statistical analysis. 
Descriptive statistics were used to describe 
demographic and disease characteristics of the 
patients. Percentages and frequencies were used for 
the categorical variables, while means and standard 
deviations were calculated for the continuous 
variables. The characteristics of the whole sample 
were presented. 
Ethical approval 
Institutional Review Board, Faculty of Pharmacy & 
Health Sciences, University of Balochistan, Pakistan 
approved the study. Additionally, permission to 
conduct the study was taken from the medical 
superintendent of the respective institutes.  
 
RESULTS: 
Demographic characteristics of the study 
respondents 
Table 1 shows the demographic characteristics of 
the patients. 
 
Table 1: Demographic characteristics of the patients (N = 117) 
Characteristics Frequency Percent 
Institute 
SPHQ 
BINUQ 
 
57 
60 
 
48.7% 
51.3 
Age group 
10-20 year 
21-31 year 
32-42 year 
43-53 year 
 >53 year 
 
09 
19 
24 
39 
26 
 
7.7% 
16.2% 
20.5% 
33.3% 
22.2% 
Gender 
Male 
Female 
 
57 
60 
 
48.7% 
51.3% 
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Disease related characteristics of the respondents 
Table 2 describes that all the patients enrolled, with 
all patients having hypertension. 7.7 % patients had 
NIDDM and 1.7% patients IDDM. 4.3% patients had 
IHD, 78.6% LVH and 80.34% CMP. 31.6% of 
patients were suffering from Systolic dysfunction and 
6.8% from Diastolic Dysfunction (Table 2). 
 
Table 2: Disease related characteristics of the study respondents 
Characteristics Frequency Percentage 
End-stage Renal Disease (ESRD) 
Yes 
No 
 
117 
0 
 
100% 
0% 
Hypertension (HTN) 
Yes 
No 
 
117 
0 
 
100% 
0% 
Non-Insulin Dependent Diabetes Myelitis (NIDDM) 
Yes 
No  
 
9 
108 
 
7.7% 
92.3% 
Insulin Dependent Diabetes Myelitis (IDDM) 
Yes 
No 
 
2 
115 
 
1.7% 
98.3% 
Ischemic Heart Disease (IHD)  
Yes 
 No 
 
5 
112 
 
4.3% 
95.7% 
Left Ventricular Hypertrophy (LVH) 
Yes 
No 
 
92 
25 
 
78.6% 
21.4% 
Left Ventricular Dysfunction (LVD) 
Systolic Dysfunction 
Diastolic Dysfunction 
 Normal L.V Function 
 
37 
8 
72 
 
31.6% 
6.8% 
61.5% 
Cardio-myopathy (CMP) 
Yes 
No 
 
94 
23 
 
80.3% 
19.7% 
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Vascular access duration and frequency of HD 
94% patients were accessed through arterio venous 
fistula for hemodialysis and 6% through central 
venous catheterization (Table 3). The vast majority of 
the patients (97.4%) were recipients of hemodialysis 
twice a week, 56% of the patients were on dialysis 
for 1-3 years or longer (Table 3). 
 
Table 3: Vascular access duration and frequency of HD 
Characteristics Frequency Percentage 
Duration Of Hemodialysis 
6 Months 
1 Year 
1-3 Years 
4-6 Years 
More than 6 Years 
 
5 
46 
56 
9 
1 
 
4.3% 
39.3% 
47.9% 
7.7% 
0.9% 
Hemodialysis (Frequency per week) 
2/ week 
3/ week                   
 
114 
03 
 
97.4% 
2.6% 
Arterio-Venous Fistula (AVF) 
Yes 
No 
 
110 
7 
 
94% 
6% 
Central venous Catheterization (CVC) 
Yes 
No 
 
7 
110 
 
6% 
94% 
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Signs and symptoms of the study respondents 
57.3% of the patients had shortness of breath (table 
4). Out of all patients, 35.0% had pedal edema, 4.3%  
 
had asities, 36.8% had palpitation and 20.5% had 
pericardial effusion (Table 4).  
 
Table 4: Signs and symptoms of the study respondents 
Characteristics Frequency Percentage 
Shortness Of Breath (SOB) 
Yes 
No 
 
67 
50 
 
57.3% 
42.7% 
Pedal Edema 
Yes 
 No 
 
41 
76 
 
35.0% 
65.0% 
Asities 
Yes 
No 
 
5 
112 
 
4.3% 
95.7% 
Palpitation 
Yes 
No 
 
43 
74 
 
36.8% 
63.2% 
Pericardial Effusion (PE) 
Yes 
 No  
 
24 
93 
 
20.5% 
79.5% 
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The prognosis and de-novo CHF is presented in 
Table 6. From 117 patients, 45 (38.4%) developed 
CHF whereby only 4 (3.4%) developed both systolic 
and diastolic dysfunction. Out of the reported 45 
CHF patients, de-novo CHF was reported in 13 
(28.8%) while recurrence of CHF was observed 
among 26 (57.7%). Death was reported in eleven 
patients throughout the study period (Table 5).   
 
Table 5: Prognosis and de-novo congestive heart failure 
Characteristics Frequency Percent 
Congestive Heart Failure  
Yes 
No 
 
45 
72 
 
38.46% 
61.5% 
Systolic plus Diastolic Dysfunction 
Yes 
No 
 
4 
113 
 
3.4% 
96.6% 
New (de-novo) Congestive Heart Failure   
Yes 
No 
 
13 
32 
 
28.8% 
71.2% 
Recurrence of Congestive Heart Failure 
Yes 
No 
 
26 
19 
 
57.7% 
42.3% 
Deaths 
Yes 
No 
 
11 
34 
 
24.4% 
75.6% 
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DISCUSSION: 
Frequency of CHF 
45 ESRD patients out of 117 had established CHF, 
which were confirmed clinically based by 
echocardiography (Table 5). This percentage is high 
compared to other reported studies. The prevalence 
of congestive heart failure in hemodialysis recipients 
was 9% in the study by Parfrey et al [17] and higher 
than 31% reported by Harnett et al[7] (Harnett et al., 
1995). Clinical manifestations of congestive heart 
failure are already present in approximately a third of 
new dialysis patients [18]. Compared with the 
general population, dialysis patients have a 10 to 
20 times greater incidence of cardiovascular death 
[19]. The reported incidence of heart failure is 
substantially higher than that of acute coronary 
syndrome (29 events/1,000 patient-years) in long-term 
dialysis patients [20]. The incidence of heart failure in 
prevalent dialysis patients is estimated at 71 
events/1,000 patient years, substantially higher than 
the incidence of acute coronary syndrome (29 
events/1,000 patient-years) [21]. There may be a 
number of reasons for the high incidence of CHF in 
the ESRD population in our study. Firstly, Quetta 
being the capital city of the province, patients come 
from rural areas to get healthcare facilities. 
Secondly, a large number of patients from across 
the border of Afghanistan also come for the 
treatment. Patients in rural areas typically have a 
poor health care system and have very low 
economic conditions; consequently, they rely on 
home remedies for the treatment of severe disease 
conditions. In such rural areas, mythical and 
spiritual beliefs are negative aspect of treatment 
leading to a worsening of disease before presenting 
to specialist centres in urban settings. Herbal 
treatment is one of the most notorious ailments in 
such areas, which may be the main reason of 
worsening the disease specially affecting the 
deterioration of the cardiovascular and renal 
systems before presentation. Another important fact 
is the existences of non-qualified practitioners that 
also contribute to the deterioration of health 
conditions in such areas. Furthermore, the lack of 
awareness and late referral of patients from general 
practitioners and physicians to the nephrologists in 
deprived health care systems may also lead to a 
higher incidence of ESRD and CHF in our study 
population.  
Typically when the patients are referred to 
nephrologists, they already have progression of 
kidney disease and most of the time patients come 
to nephrologists with advanced stage renal disease 
or even with renal insufficiency. In such 
circumstances, nephrologists have limited choice of  
 
treatment, with patient advised that renal 
replacement therapy may be the only option. The 
suitable choice of renal replacement therapy for 
nephrologists is to initiate the patient on 
hemodialysis. Initiation of hemodialysis requires 
vascular access, with central venous catheterization 
(CVC) adopted for prompt hemodialysis execution. 
Meanwhile, an arterio-venous fistula (AVF) is 
performed surgically, which takes almost three to 
four weeks in maturation. After this, continuous 
hemodialysis is executed by means of AVF. AVF is 
more appropriate for hemodialysis compared to 
CVC. This is true in our study whereby 94% of the 
patients had vascular access to AVF as compared to 
CVC (Table 3). 
Prognosis 
CHF is associated with poor outcome in patients who 
are on maintenance hemodialysis [22]. Left 
ventricular systolic dysfunction, per se, is an 
independent cardiovascular risk factor for poor 
prognosis, even in patients with normal renal 
function, in the elderly population and in patients 
with asymptomatic LV systolic dysfunction. It is 
likely that decreased LVEF may indicate a similar 
adverse prognosis in ESRD patients, despite 
transplantation [23]. This reflects our study 
outcomes, where recurrence of CHF was 57.7% and 
24.4% mortality in CHF group that results in adverse 
prognosis. A significant proportion of cardiovascular 
events in long-term dialysis patients are caused by 
heart failure, and the presence of heart failure are 
predictive of a poor prognosis. Cardiac hypertrophy 
and systolic dysfunction are now widely recognized 
as powerful predictors of adverse prognosis in the 
long-term dialysis population. In our study 
population 78.6% patients had LVH, and 31.6% 
patients had systolic dysfunction, both contribute in 
poor prognosis. Congestive heart failure is itself a 
complex cardiovascular complication its management 
is very challenging.  
Four patients were found to have both systolic and 
diastolic dysfunctions with 13 patients (29%) 
developing de novo CHF (Table 5). Frequently re-
hospitalization was required due to worsening of the 
cardiovascular conditions subsequent of CHF 
resulting in 26 patients that is 57.7% (Table 5). In 
CHF group, 11 patients died resulting 24.4% deaths 
in this specific group during the study period. These 
circumstances reflect the poor prognosis of CHF in 
ESRD population of our study. 
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CONCLUSION: 
The incidence of CHF was relatively high in our 
study population of ESRD. Frequent recurrence of 
the disease, re-hospitalization and enhanced mortality 
in our study population is evident of adverse 
prognosis of CHF in ESRD population. 
Cardiovascular diseases must not be considered 
separately in ESRD patients, appropriate 
management and correction of comorbid conditions 
improves the disease conditions to some extent. 
 
Limitations 
The limited sample size is an issue while discussing 
about the generalizability of the results.   
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